Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

504.10INR
3:48pm IST
Change (% chg)

Rs-6.90 (-1.35%)
Prev Close
Rs511.00
Open
Rs512.40
Day's High
Rs515.90
Day's Low
Rs501.50
Volume
2,725,047
Avg. Vol
4,036,174
52-wk High
Rs838.00
52-wk Low
Rs389.35

Latest Key Developments (Source: Significant Developments)

Aurobindo Pharma Sept-Qtr Consol Profit Rises
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Aurobindo Pharma Ltd ::INTERIM DIVIDEND OF 1.25 RUPEES PER SHARE.SEPT QUARTER CONSOL PROFIT 6.40 BILLION RUPEES VERSUS 6.12 BILLION RUPEES LAST YEAR.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 56 BILLION RUPEES VERSUS 47.51 BILLION RUPEES LAST YEAR.  Full Article

FDA Says Aurobindo Pharma USA's Ranitidine Tablets Contain Unacceptable Levels Of NDMA
Friday, 8 Nov 2019 

Nov 8 (Reuters) - FDA::FDA - VOLUNTARY RECALL OF AUROBINDO PHARMA USA'S OTC RANITIDINE TABLETS (150MG), PRESCRIPTION RANITIDINE CAPSULES (150 & 300MG), RANITIDINE SYRUP (15MG/ML).FDA SAYS AUROBINDO PHARMA USA'S RANITIDINE TABLETS CONTAIN UNACCEPTABLE LEVELS OF N-NITROSODIMETHYLAMINE (NDMA).  Full Article

Aurobindo Pharma Says SEBI Passed Adjudication Order Against Co And Promoters
Tuesday, 24 Sep 2019 

Sept 24 (Reuters) - Aurobindo Pharma Ltd ::SEBI PASSED ADJUDICATION ORDER AGAINST COMPANY AND PROMOTERS.SEBI HAS IMPOSED PENALTY OF 131 MILLION RUPEES AGAINST PROMOTERS AND 20 MILLION RUPEES AGAINST THE COMPANY.  Full Article

India's Aurobindo Pharma March-Qtr Consol Net Profit Rises
Tuesday, 28 May 2019 

May 28 (Reuters) - Aurobindo Pharma Ltd ::MARCH QUARTER CONSOL NET PROFIT 5.85 BILLION RUPEES VERSUS PROFIT OF 5.29 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL INCOME FROM OPERATIONS 52.02 BILLION RUPEES VERSUS 39.89 BILLION RUPEES LAST YEAR.MARCH QUARTER EXCEPTIONAL ITEM 361.8 MILLION RUPEES.AUROBINDO PHARMA-APPROVED SCHEME OF AMALGAMATION OF ITS UNITS WITH CO.  Full Article

India's Aurobindo Pharma To File With Federal Court Denying Each Of Relevant Accusations
Tuesday, 14 May 2019 

May 14 (Reuters) - Aurobindo Pharma Ltd ::VARIOUS U.S. STATES FILED 2ND LAWSUIT ALLEGING AUROBINDO, OTHERS VIOLATED ANTITRUST LAWS BY FIXING PRICES AND ALLOCATING CUSTOMERS.CO TO FILE PAPERS WITH FEDERAL COURT IN DUE COURSE DENYING EACH OF RELEVANT ACCUSATIONS.DOES NOT, AT THIS TIME, ANTICIPATE THAT THESE MATTERS WILL HAVE A MATERIAL IMPACT ON CO'S OPERATIONS OR BUSINESS RESULTS.  Full Article

Health Canada Says Auro Pharma Voluntarily Recalls One Lot Of Auro-Irbesartan HCT Tablets Because Of Nitrosamine Impurity
Friday, 19 Apr 2019 

April 18 (Reuters) - Aurobindo Pharma Ltd ::HEALTH CANADA - AURO PHARMA INC VOLUNTARILY RECALLS ONE LOT OF AURO-IRBESARTAN HCT TABLETS BECAUSE OF NITROSAMINE IMPURITY.  Full Article

Aurobindo Pharma's U.S. Unit Recalled Some Amlodipine Valsartan Tablets, Valsartan Hctz Tablets, Valsartan Tablets On Dec 31
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Aurobindo Pharma Ltd ::US UNIT INITIATED VOLUNTARY RECALL OF 80 LOTS OF AMLODIPINE VALSARTAN TABLETS , VALSARTAN HCTZ TABLETS, VALSARTAN TABLETS ON DEC 31.SAYS VALUE OF PRODUCTS BEING RECALLED IS NOT MATERIAL .  Full Article

Aurobindo Pharma Gets U.S. FDA Approval For Vecuronium Bromide Injection
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Aurobindo Pharma Ltd ::GETS USFDA APPROVAL FOR VECURONIUM BROMIDE INJECTION.PRODUCT WILL BE LAUNCHED IN Q4FY19.  Full Article

India's Aurobindo Pharma Gets U.S FDA Approval For Potassium Chloride ER Tablets
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aurobindo Pharma Ltd ::GETS U.S FDA APPROVAL FOR POTASSIUM CHLORIDE ER TABLETS.SAYS POTASSIUM CHLORIDE TABLETS ARE INDICATED FOR THE TREATMENT OF HYPOKALEMIA.PRODUCT WILL BE LAUNCHED IN JANUARY 2019.  Full Article

Aurobindo Pharma Says Co Not Yet Served With Legal Notice W.R.T. U.S. Suit Over Impurities
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Aurobindo Pharma Ltd ::AUROBINDO PHARMA CLARIFIES ON NEWS REPORT ON CO FACING U.S. SUIT OVER IMPURITIES.HAVE NOT YET BEEN SERVED WITH LEGAL NOTICE.  Full Article